The impact of rifaximin in the prevention of bacterial infections in cirrhosis

M. Mariani, V. Zuccaro, S. F.A. Patruno, L. Scudeller, P. Sacchi, A. Lombardi, M. Vecchia, P. Columpsi, P. Marone, G. Filice, R. Bruno

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin.

PATIENTS AND METHODS: We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment.

RESULTS: The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95% CI 0.20-0.40, p < 0.001).

CONCLUSIONS: Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients.

Original languageEnglish
Pages (from-to)1151-1158
Number of pages8
JournalEuropean Review for Medical and Pharmacological Sciences
Volume21
Issue number5
Publication statusPublished - Mar 1 2017

Fingerprint

rifaximin
Bacterial Infections
Fibrosis
Infection
Therapeutics
Survival Rate
Databases
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The impact of rifaximin in the prevention of bacterial infections in cirrhosis. / Mariani, M.; Zuccaro, V.; Patruno, S. F.A.; Scudeller, L.; Sacchi, P.; Lombardi, A.; Vecchia, M.; Columpsi, P.; Marone, P.; Filice, G.; Bruno, R.

In: European Review for Medical and Pharmacological Sciences, Vol. 21, No. 5, 01.03.2017, p. 1151-1158.

Research output: Contribution to journalArticle

@article{c846f1203cc544dea22fb5cadd06f2c8,
title = "The impact of rifaximin in the prevention of bacterial infections in cirrhosis",
abstract = "OBJECTIVE: Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin.PATIENTS AND METHODS: We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment.RESULTS: The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95{\%} CI 0.20-0.40, p < 0.001).CONCLUSIONS: Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients.",
author = "M. Mariani and V. Zuccaro and Patruno, {S. F.A.} and L. Scudeller and P. Sacchi and A. Lombardi and M. Vecchia and P. Columpsi and P. Marone and G. Filice and R. Bruno",
year = "2017",
month = "3",
day = "1",
language = "English",
volume = "21",
pages = "1151--1158",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "5",

}

TY - JOUR

T1 - The impact of rifaximin in the prevention of bacterial infections in cirrhosis

AU - Mariani, M.

AU - Zuccaro, V.

AU - Patruno, S. F.A.

AU - Scudeller, L.

AU - Sacchi, P.

AU - Lombardi, A.

AU - Vecchia, M.

AU - Columpsi, P.

AU - Marone, P.

AU - Filice, G.

AU - Bruno, R.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - OBJECTIVE: Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin.PATIENTS AND METHODS: We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment.RESULTS: The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95% CI 0.20-0.40, p < 0.001).CONCLUSIONS: Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients.

AB - OBJECTIVE: Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin.PATIENTS AND METHODS: We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment.RESULTS: The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95% CI 0.20-0.40, p < 0.001).CONCLUSIONS: Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients.

UR - http://www.scopus.com/inward/record.url?scp=85026299700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026299700&partnerID=8YFLogxK

M3 - Article

C2 - 28338174

AN - SCOPUS:85026299700

VL - 21

SP - 1151

EP - 1158

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 5

ER -